ALB vs NEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong recent price run-up (+115.4% over 1Y), the company is unprofitable (negative profit and operating margins), has negative earnings growth (YoY), and trades at an extremely high forward P/E of 82.85. While the balance sheet shows a healthy current ratio and manageable debt/equity of 0.37, the lack of Altman Z-Score and Graham Number, combined with deteriorating profitability and insider selling, raises serious concerns about sustainability. The analyst target price of $165.06 implies 13% downside from current levels, reinforcing overvaluation relative to fundamentals.
NEM shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics. Price trades at a 155.7% premium to fair value estimate ($44.73), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ALB vs NEM: Head-to-Head Comparison
This page compares Albemarle Corporation (ALB) and Newmont Corporation (NEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.